Current Cancer Drug Targets


Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204

Personal Subscription
Become EABM
Become Reviewer

Glycogen Synthase Kinase-3 Beta; A New Target in Pancreatic Cancer?

Volume:7   Issue: 3
Pp: 209-215
G. Garcea, M. M. Manson, C. P. Neal, C. J. Pattenden, C. D. Sutton, A. R. Dennison and D. P. Berry
DOI: 10.2174/156800907780618266

Metastasis-Associated Protein S100A4: Spotlight on its Role in Cell Migration

Volume:7   Issue: 3
Pp: 217-228
S. Tarabykina, T. R. L. Griffiths, E. Tulchinsky, J. K. Mellon, I. B. Bronstein and M. Kriajevska
DOI: 10.2174/156800907780618329

Non-Homologous DNA End Joining in Anticancer Therapy

Volume:7   Issue: 3
Pp: 243-250
Elzbieta Pastwa and Mariusz Malinowski
DOI: 10.2174/156800907780618284

The Kinase Inhibitor Imatinib - An Immunosuppressive Drug?

Volume:7   Issue: 3
Pp: 251-258
D. Wolf, H. Tilg, H. Rumpold, G. Gastl and A. M. Wolf
DOI: 10.2174/156800907780618293

MUC1 is a Promising Therapeutic Target for Prostate Cancer Therapy

Volume:7   Issue: 3
Pp: 259-271
Y. Li and P. J. Cozzi
DOI: 10.2174/156800907780618338

Current Status and Future of Target-Based Therapeutics

Volume:7   Issue: 3
Pp: 273-284
Ryoko Suzuki, Parijatha Rao and Shiro Sasaguri
DOI: 10.2174/156800907780618275

Conditionally Replicating Adenoviruses for Cancer Treatment

Volume:7   Issue: 3
Pp: 285-301
Youssef Jounaidi, Joshua C. Doloff and David J. Waxman
DOI: 10.2174/156800907780618301